Sutro Biopharma (STRO) Liabilities and Shareholders Equity (2017 - 2025)

Sutro Biopharma (STRO) has 9 years of Liabilities and Shareholders Equity data on file, last reported at $173.8 million in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 55.11% year-over-year to $173.8 million; the trailing twelve-month figure through Dec 2025 stood at $967.3 million (down 44.14% YoY), and the FY2025 full-year result was $173.8 million, down 55.11% from the prior year.
• Liabilities and Shareholders Equity slipped to $173.8 million in Q4 2025, from $209.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $489.0 million in Q2 2024 to a low of $173.8 million in Q4 2025.
• A 5-year average of $367.6 million and a median of $378.5 million in 2021 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity soared 133.0% in 2021 and plunged 55.11% in 2025, its largest moves.
• Tracing STRO's Liabilities and Shareholders Equity over 5 years: stood at $341.4 million in 2021, then rose by 19.2% to $406.9 million in 2022, then rose by 15.68% to $470.7 million in 2023, then retreated by 17.74% to $387.2 million in 2024, then sank by 55.11% to $173.8 million in 2025.
• Business Quant data shows STRO's Liabilities and Shareholders Equity at $173.8 million in Q4 2025, $209.7 million in Q3 2025, and $262.4 million in Q2 2025.